Latest Cochlear (Asx:Coh) News

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the first half of 2025, with payments available in multiple currencies based on shareholder location.

Cochlear Limited has extended its on-market share buy-back program, allowing the company to repurchase up to AUD 75 million of its fully paid ordinary shares until August 2026.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Cochlear Limited reported a 4% revenue rise in FY25, driven by strong implant sales and launched the world’s first smart cochlear implant system. The company forecasts up to 17% profit growth in FY26, underpinned by innovation and expanding markets.

Cochlear Limited has announced a fully franked ordinary dividend of AUD 2.15 per share for the six months ending June 2025, payable in October with multi-currency options for shareholders.

Cochlear Limited has reported steady financial growth with a 4% rise in sales revenue and a 9% increase in underlying net profit for the fiscal year ending June 2025, maintaining its dividend payout.

Cochlear Limited has secured FDA approval for its latest Nucleus Nexa System and Kanso 3 sound processors, setting the stage for a US market debut in early FY26.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.